Skip to content

Comparative Study on Postoperative Analgesia With Transversus Abdominis Plane Block to Local Anesthetic Infiltration With Ropivacaine in Laparoscopic Abdominal Surgery

Comparative Study on Postoperative Analgesia With Transversus Abdominis Plane Block to Local Anesthetic Infiltration With Ropivacaine in Laparoscopic Abdominal Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05995301
Enrollment
100
Registered
2023-08-16
Start date
2022-03-12
Completion date
2023-02-25
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Laparoscopic Abdominal Surgery, Local Infiltration, Ropivacaine

Keywords

Ropivacaine, TAP Block, Analgesia, Laparoscopic abdominal surgery

Brief summary

The goal of this clinical trial is to compare the postoperative analgesic efficacy of ultrasound-guided TAP block with Local Anesthetic Infiltration of ropivacaine in patients undergoing laparoscopic surgery. The main question it aims to answer is: • If Transversus Abdominis Plane block with Ropivacaine will produce long duration of analgesia than the Local Anesthetic Infiltration with ropivacaine after laparoscopic abdominal surgery .

Detailed description

Pain is a natural phenomenon. Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Pain is distressing and detrimental in post-operative patients. Management of post-operative pain has been a challenge to anesthetists. Pain treatment increase speed of recovery, minimum patient suffering, decrease length of stay, reduced hospital costs, increased patient satisfaction, increase productivity and quality of life. Peripheral nerve blockade or field block with local anesthesia is helpful in managing postoperative pain effectively whilst avoiding complication associated with intravenous narcotics or neuraxial blockade. Regional block will help in reduction of dose and frequency of intravenous narcotics used in postoperative period, hence minimizing the side effects of narcotics. Ultrasound guided abdominal nerve blocks are increasingly being used for anaesthesia and analgesia. The Transversus Abdominis Plane (TAP) block is a peripheral nerve block that results in anesthesia of the abdominal wall. This plane represents an anatomical potential space with nerves leaving the plane to innervate the abdominal muscles and skin. Transversus abdominis plane block (TAP block) is a novel procedure to provide postoperative analgesia following laparoscopic surgery. Ropivacaine has a greater degree of motor sensory differentiation. Ropivacaine has been safely used up to the dose of 200 mg (100 ml of 0.2% ropivacaine) as a field block for post operative analgesia. We are giving a larger volume of ropivacaine (20 ml on each side) expecting to cover the upper abdomen when TAP block is performed via posterior approach. NULL HYPOTHESIS There is no difference in post operative analgesia with Transversus Abdominis Plane block and local anesthetic infiltration after laparoscopicabdominal surgery General objective 1\. To compare the efficacy of Transversus Abdominal plane block and local anesthetic infiltration after laparoscopic abdominal surgery Specific objective 1. To compare the visual analog score (VAS) between two groups 2. To compare time to first analgesic requirement between two groups. 3. To compare the total dose of analgesia in 24 hours between the two groups

Interventions

DRUGRopivacaine in Transversus abdominis plane

This group received 20ml of Ropivacaine 0.2% Injectable Solution in bilateral transversus abdominis plane at the end of surgery

DRUGRopivacaine in Local infiltration at port site

This group received local infiltration of 20ml of Ropivacaine 0.2% Injectable Solutionat port sites at the end of surgery

Sponsors

National Academy of Medical Sciences, Nepal
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Masking description

Patients were randomly assigned to two groups having 50patients in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesia assistant who was not involved in the study.

Intervention model description

Patients were randomly assigned to two groups having 50patients in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesia assistant who was not involved in the study.

Eligibility

Sex/Gender
ALL
Age
25 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Adult patients of either sex aged 25-70 years 2. ASA physical status I or II 3. Patient posted for elective abdominal laparoscopic surgery.

Exclusion criteria

1. Any absolute contraindications to peripheral nerve blockade 2. History of Hypersensitivity to Drugs 3. Uncontrolled Diabetes Mellitus, Renal Failure, Hepatic failure 4. History of neuromuscular or psychiatric disease 5. Patient receiving psychotropic drug, chronic analgesic therapy 6. Pregnancy 7. Patient weight less than 50 kg

Design outcomes

Primary

MeasureTime frameDescription
Duration of analgesiaTime Frame: upto first 24 hour after interventionVisual analog scale at rest

Secondary

MeasureTime frameDescription
Duration of analgesiaTime Frame: upto first 24 hour after interventionVisual analog scale on movement

Other

MeasureTime frameDescription
Time to first rescue analgesiaTime Frame: upto first 24 hour after interventionThe time of first complaint of pain by the patient.
Total pethidine consumptionTime Frame: upto first 24 hour after interventionAt any point of time when VAS was\>3, injection pethidine 0.5 mg/kg and injection promethazine 0.25 mg/kg was given via intravenous route
Total ketorolac consumptionTime Frame: upto first 24 hour after interventionWhen pain persisted for more than 15 min after giving intravenous pethidine, injection ketorolac 30 mg intravenous was given

Countries

Nepal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026